Showing results (161-170 of 192) with videos related to
Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.Blood Advances|April 23, 2021
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromesGrace A Ward, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.Oncotarget|December 30, 2016
Recurrent genetic defects on chromosome 5q in myeloid neoplasmsNaoko Hosono, Hideki Makishima, Reda Mahfouz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.International Journal of Molecular Sciences|February 25, 2023
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic SyndromesGrace A Ward, Robert P Dalton, Benjamin S Meyer, et al.Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsGisela Caceres, Kathy McGraw, Bon Ham Yip, et al.Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromesSriram Sundaravel, Ryan Duggan, Tushar Bhagat, et al.Pageof 20